Vistin Pharma ASA Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	74.76	62.75	45.6	-4.72	24.87
Depreciation & Amortization	22.53	19.03	17.35	12.28	10.61
Other Operating Activities	21.08	17.7	12.92	-1.29	7.13
Change in Accounts Receivable	-	-3.12	12.14	-20.81	-12.76
Change in Inventory	-	3.51	3.28	-40.54	-11.12
Change in Other Net Operating Assets	-39.66	7.99	-0.69	44.57	-5.05
Operating Cash Flow	78.71	107.86	90.59	-10.51	13.68
Operating Cash Flow Growth	-27.02%	19.06%	-	-	-
Capital Expenditures	-16.68	-40.8	-17.9	-64.29	-31.94
Other Investing Activities	-	0.51	0.22	0.03	0.27
Investing Cash Flow	-16.68	-40.3	-17.68	-64.26	-31.68
Short-Term Debt Issued	-	-	-	45.14	-
Total Debt Issued	-	-	-	45.14	-
Short-Term Debt Repaid	-	-	-45.14	-	-
Long-Term Debt Repaid	-	-1.2	-0.9	-2.59	-0.84
Total Debt Repaid	-	-1.2	-46.05	-2.59	-0.84
Net Debt Issued (Repaid)	-	-1.2	-46.05	42.55	-0.84
Common Dividends Paid	-55.43	-77.59	-	-	-22.17
Other Financing Activities	-2.97	-2.19	-2.1	-2.09	-0.29
Financing Cash Flow	-58.4	-80.97	-48.14	40.46	-23.3
Miscellaneous Cash Flow Adjustments	-	-0	0	0	0
Net Cash Flow	3.63	-13.41	24.77	-34.31	-41.29
Free Cash Flow	62.03	67.05	72.69	-74.8	-18.26
Free Cash Flow Growth	-7.49%	-7.75%	-	-	-
Free Cash Flow Margin	13.71%	15.61%	16.58%	-24.54%	-6.55%
Free Cash Flow Per Share	1.40	1.51	1.64	-1.69	-0.41
Cash Interest Paid	-	2.19	2.1	2.09	0.29
Levered Free Cash Flow	14.11	36.75	54.19	-81.62	-30.41
Unlevered Free Cash Flow	20.99	38.21	55.61	-80.28	-30.19
Change in Working Capital	-39.66	8.38	14.73	-16.78	-28.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.